Skip to Main Content

Two months ago, a Senate report suggested that Insys Therapeutics (INSY) provided $2.5 million to a patient advocacy group in order to influence usage and providing of its Subsys opioid painkiller. The link, however, was not fully explored, but a new essay in a bioethics blog takes us a step closer to understanding how that relationship may benefit the company.

To do so requires a familiar exercise: follow the money. But it also helps to understand why Subsys and a handful of similar powerful medications, all of which are forms of fentanyl, are often favored by doctors for treating so-called breakthrough cancer pain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!